Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Harvoni Approved for Genotype 2 Hep C, Zytiga for Earlier Line
February 19, 2018
- PhRMA Wants Japan Put on “Priority Watch List” in USTR’s Trade Barrier Report
February 16, 2018
- MHLW OKs Authorized Generics for Aimix, Cravit IV, Takepron; June Listing Eyed
February 16, 2018
- 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
- MHLW Launches Startup Support Project
February 16, 2018
- MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
- Label Revisions Ordered for Gardenia Fruit Kampo Agents, Stocrin
February 14, 2018
- Japan Cabinet Adopts Bill to Require Generic Use for Welfare Recipients
February 13, 2018
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- MHLW Cautions on Hepatitis E Virus Infection due to Blood Products for Transfusion
February 2, 2018
- MHLW Panel Calls for Single-Product, Single-Price Transactions for Blood Products
February 2, 2018
- Proper Use of Ethical Moisturizing Agents Added to Supplementary Opinion for FY2018 Reimbursement Reform: Chuikyo
February 1, 2018
- Drug Pricing Reform Draws Mixed Opinions: Public Comments
February 1, 2018
- Drug Makers Looking to Adopt Continuous Manufacturing, Anticipating 30-40% Lower Production Costs: PMDA Official
January 31, 2018
- MHLW to Create Framework for Announcing Results of Clinical Research in Tandem with Enforcement of Clinical Research Law
January 29, 2018
- Chuikyo to Continue Discussions on Drug Pricing Reform “After Verifying Impact on Stakeholders”; Further Discussions on Essential Drugs
January 29, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…